Posluma PET scan to guide focal therapy for prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial tests if a newer imaging test called a Posluma PET scan can help doctors plan focal therapy (treatment that targets only the cancer) for men with early prostate cancer. It aims to see if this scan helps monitor the disease after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with prostate cancer.
- The cancer is intermediate-risk and still inside the prostate (organ-confined).
- Your doctor has said you are a good candidate for focal therapy.
- You are 18 years old or older.
- Your doctor expects you to live at least 10 more years.
- You are willing to sign a consent form to join the study.
- You have not had any prior treatment for prostate cancer.
- You do not have severe heart, kidney, liver, or other health problems that would make the study unsafe.
- You are not allergic to the Posluma contrast used in the scan, and you can have a PET or MRI without issues like severe claustrophobia or incompatible metal implants.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special PET scan (called PSMA, which pictures prostate cancer cells) can help doctors better find any remaining or spread of prostate cancer when your PSA level is rising again. It's for people who are planning radiation therapy, and the goal is to see if the scan changes the treatment plan.
This trial tests a new PET scan (a type of imaging that uses a radioactive tracer) to see how well it can find prostate cancer after focal therapy. If you join, you'll get the scan before and after your treatment to help doctors see if any cancer is left.
This trial uses a special PET scan (POSLUMA) before and after radiation to see if it helps treat prostate cancer that has spread to a few spots outside the pelvis. It's for men whose cancer still responds to hormone therapy and who have not had widespread spread.
This trial tests a new type of PET scan to see how well it finds leftover cancer after you've had focal therapy (treatment to just part of the prostate) for intermediate-risk prostate cancer in the last 9 months.
This early-phase study tests a precise, targeted radiation treatment for prostate cancer, using a special PET scan to help plan exactly where to treat. It may help reduce the amount of radiation to surrounding tissues while treating the cancer.
This study tests a new way to treat prostate cancer that is not visible on MRI but is detected by a special PET scan. The treatment is a focal therapy that targets only the cancer while sparing healthy tissue, and it aims to control the cancer with fewer side effects.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.